Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Histamine H3 receptor antagonists

An alkyl, general formula technology, applied in the field of new compounds, can solve the problem of not giving the pharmacological data of the compound and so on

Inactive Publication Date: 2008-07-09
HIGH POINT PHARMA
View PDF26 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No pharmacological data are given for the compounds prepared

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Histamine H3 receptor antagonists
  • Histamine H3 receptor antagonists
  • Histamine H3 receptor antagonists

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0440] Example 1 (General Method A)

[0441] 1-[5-(4-Chlorophenyl)pyridin-2-yl]-4-isopropylpiperazine, dihydrochloride

[0442]

[0443]2-Chloro-5-(4-chlorophenyl)pyridine (500 mg, 2.23 mmol), DMSO (2.0 mL) and 1-isopropylpiperazine (3 mL, 23.4 mmol) were stirred and heated in a 100 °C oil bath overnight. The reaction mixture was poured into water (75 mL), and the solid was isolated by filtration, washed with water and dried. The crude product was purified by column chromatography on silica gel (Kiselgel 60, 0.040-0.63 mesh), washing with a mixture of ethyl acetate and methanol (4:1). Collection of appropriate fractions afforded 600 mg (85%) of 1-[5-(4-chlorophenyl)-pyridin-2-yl]-4-isopropylpiperazine.

[0444] 1 H NMR (300MHz, CDCl 3 )δ1.10 (d, 6H), 2.63-2.68 (m, 4H), 2.75 (septet, 1H), 3.59-3.66 (m, 4H), 6.69 (d, 1H), 7.35-7.45 (m, 4H ), 7.67 (dd, 1H), 8.40 (d, 1H).

[0445] The free base was dissolved in a mixture of 0.5N hydrochloric acid solution and ethanol. A...

Embodiment 2

[0450] Embodiment 2 (general method A)

[0451] 1-Isopropyl-4-[5-(4-methoxyphenyl)pyridin-2-yl]piperazine, dihydrochloride

[0452]

[0453] 2-Chloro-5-(4-methoxyphenyl)pyridine (200 mg, 0.91 mmol), anhydrous DMSO (2.0 mL) and 1-isopropylpiperazine (500 mg, 3.9 mmol) were stirred and heated at 130° C. Heat in an oil bath overnight, then heat at 150°C for 4 hours, leave at room temperature for 2 days, and finally heat at 140°C overnight. The reaction mixture was cooled, then poured into water (100 mL). The mixture was extracted with ethyl acetate (100 mL), and the organic extract was washed with water and dried (MgSO 4 ). The solvent was evaporated to give a solid residue which was dissolved in 0.5N hydrochloric acid (20 mL). A small amount of insoluble solid was removed by filtration and the aqueous solution was evaporated to give a residue which was re-evaporated with absolute ethanol. The resulting solid was recrystallized from absolute ethanol to afford 210 mg (60%)...

Embodiment 3

[0458] Embodiment 3 (general method A)

[0459] 1-Isopropyl-4-[5-(4-trifluoromethoxyphenyl)pyridin-2-yl]piperazine, dihydrochloride

[0460]

[0461] Starting from 2-chloro-5-(4-trifluoromethoxyphenyl)pyridine and 1-isopropylpiperazine, in a similar manner to that described in Example 1, the title compound was prepared.

[0462] Mp=271-273°C.

[0463] 1 H NMR (300MHz, DMSO-d 6 )δ1.32(d, 6H), 3.05-3.21(m, 2H), 3.45-3.67(m, 5H), 4.50-4.61(m, 2H), 7.28(d, 1H), 7.46(d, 2H) , 7.82 (d, 2H), 8.17 (d, 1H), 8.46 (s, 1H), 11.4 (brs, 1H).

[0464] C 19 h 22 f 3 N 3 Microanalysis of O, 2 x HCl:

[0465] Calculated value: C: 52.06%; H: 5.52%; N: 9.59%;

[0466] Measured values: C: 52.07%; H: 5.53%, N: 9.36%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.

Description

field of invention [0001] The present invention relates to novel compounds, to the use of these compounds in pharmaceutical compositions, to pharmaceutical compositions comprising said compounds, and to methods of treatment using these compounds or compositions. The compounds of the present invention exhibit high and selective binding affinity to histamine H3 receptors, and exhibit histamine H3 receptor antagonistic, inverse agonistic or agonistic activities. Thus, the compounds are useful in diseases or conditions associated with histamine H3 receptors. Background of the invention [0002] The existence of the histamine H3 receptor has been known for several years, and this receptor is currently of interest for the development of new drugs. Recently, the histamine H3 receptor has been cloned. Histamine H3 receptors are presynaptic autoreceptors located in the central and peripheral nervous systems, skin and organs such as lungs, intestines, perhaps spleen and gastrointest...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D213/74C07D213/84C07D401/04C07D213/87C07D401/08C07D413/04C07D403/04C07D413/14C07D401/12C07D241/20C07D403/12A61P3/00C07D405/06A61K31/444C07D413/10
CPCC07D401/04C07D213/74C07D213/84C07D213/87C07D241/20C07D401/08C07D401/12C07D403/04C07D403/12C07D405/06C07D413/04C07D413/10C07D413/14
Inventor R·霍尔韦格K·E·安德森J·L·索伦森J·M·伦德贝克
Owner HIGH POINT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com